A Phase 1 Adaptive Dose, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Orally Administered CORT113176 in Healthy Subjects, With an Optional Pharmacological Effects Cohort
Latest Information Update: 02 Feb 2022
At a glance
- Drugs Dazucorilant (Primary) ; Prednisone
- Indications Neurodegenerative disorders
- Focus Adverse reactions; First in man
- Sponsors Corcept Therapeutics
Most Recent Events
- 09 Oct 2020 Status changed from recruiting to completed.
- 13 Mar 2020 Status changed from not yet recruiting to recruiting.
- 12 Feb 2020 New trial record